Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10434463" target="_blank" >RIV/00216208:11150/21:10434463 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/21:43922609 RIV/00179906:_____/21:10434463 RIV/00064173:_____/21:N0000246
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=919sY0hojB" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=919sY0hojB</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14712/18059694.2021.32" target="_blank" >10.14712/18059694.2021.32</a>
Alternative languages
Result language
angličtina
Original language name
Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
Original language description
INTRODUCTION: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. CASE REPORT: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. CONCLUSION: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Acta Medica (Hradec Králové)
ISSN
1211-4286
e-ISSN
—
Volume of the periodical
64
Issue of the periodical within the volume
3
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
6
Pages from-to
187-192
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85121960803